|本期目录/Table of Contents|

[1]钟科,唐富豪,潘鑫,等.长链非编码RNA ReCAL作为肾透明细胞癌预后标志物和靶向治疗反应预测因子的研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):337-344.[doi:10.3969/j.issn.1672-271X.2021.04.001]
　ZHONG Ke,TANG Fu-hao,PAN Xin,et al.LncRNA ReCAL as aprognostic biomarker and targeted-therapy response predictor in clear cell renal cell carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(04):337-344.[doi:10.3969/j.issn.1672-271X.2021.04.001]
点击复制

长链非编码RNA ReCAL作为肾透明细胞癌预后标志物和靶向治疗反应预测因子的研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年04期
页码:
337-344
栏目:
基础研究
出版日期:
2021-08-10

文章信息/Info

Title:
LncRNA ReCAL as aprognostic biomarker and targeted-therapy response predictor in clear cell renal cell carcinoma
作者:
钟科; 唐富豪; 潘鑫; 张征宇
作者单位：233000蚌埠，蚌埠医学院研究生院(钟科)；210002 南京，东部战区总医院(原南京军区南京总医院）泌尿外科（唐富豪、潘鑫、张征宇）
Author(s):
ZHONG Ke1; TANG Fu-hao2; PAN Xin2; ZHANG Zheng-yu2
（1. Graduate School，Bengbu Medical College，Bengbu 233000，Anhui，China；2.Department of Urology，General Hospital of Eastern Theater Command，PLA，Nangjing 210002，Jiangsu，China）
关键词:
肾癌; 长链非编码RNA; 预后; 生物标志物; 靶向治疗
Keywords:
renal cell carcinoma;  long noncoding RNA;  prognosis;  biomarker;  targeted therapy
分类号:
R737.11
DOI:
10.3969/j.issn.1672-271X.2021.04.001
文献标志码:
A
摘要:
目的分析肾透明细胞癌（ccRCC）患者队列转录组数据，寻找一种可靠的长链非编码RNA（lncRNA）作为预测ccRCC患者预后的生物标记物，对患者个体化治疗方案的有效制订和改善预后提供参考。方法开发一种综合数据挖掘策略来识别3个筛选队列中的预测候选lncRNA。在2004年至2012年间收集的多中心的1908例ccRCC患者中，对所选lncRNA的预后价值进行验证，中位随访时间为96个月（IQR 46-105）。对98例接受舒尼替尼或索拉非尼治疗的患者进行lncRNA表达与临床预后的关系分析。主要临床终点是总生存期（OS）。采用单变量和多变量Cox回归、Kaplan-Meier曲线评估lncRNA表达与临床终点的相关性。结果ReCAL(与肾癌相关的lncRNA)被认为是研究队列中与OS相关最显著的lncRNA。多中心队列验证证实ReCAL的预后价值。在多变量模型中，较高的ReCAL表达与低OS相关（长海队列：HR：3.391；95%CI：2.741～4.386；P=1.344E-14。长征队列：HR：2.473；95%CI：1.062～3.251；P=0.044。东总队列：HR：2.409；95%CI：1.097～3.210；P=0.037）。ReCAL在低危Mayo Clinic SSIGN评分肿瘤患者中尤其具有预后价值。低表达ReCAL的肾癌患者表现出对舒尼替尼（HR：0.157；95%CI：0.033～0.744；P=0.020）或索拉非尼（HR：0.470；95%CI：0.229～0.646；P=0.031）靶向治疗较好的反应性。结论高表达ReCAL是ccRCC患者预后不良的独立生物标志物，也是靶向治疗反应不良的预测性生物标志物。
Abstract:
ObjectiveTo analyze the transcriptome data of patients with renal clear cell carcinoma (ccRCC) and to identify a robust long noncoding RNA (lncRNA) biomarker to predict the prognosis of patients with ccRCC, and to provide a reference for the effective formulation of individualized treatment and improvement of prognosis.MethodsAn integrative data-mining strategy was developed to identify prognostic candidate lncRNA in three discovery cohorts. The prognostic value of selected lncRNA was validated in 1908 ccRCC patients from multi-institutional cohorts collected between 2004 and 2012, with median follow-up of 96 months (IQR 46-105). A total of 98 patients who underwent sunitinib or sorafenib treatment with matched patients were analyzed for the relationship between lncRNA expression and clinical outcomes. The primary clinical endpoint was overall survival (OS). Univariable and multivariable Cox regression, Kaplan-Meier curves and Harrell’s C-index were used to evaluate the association of lncRNA expression with these end-points.ResultsRenal Cancer Associated LncRNA (ReCAL) was identified as the most significant lncRNA associated with OS in discovery cohorts. Validation in multi-institutional cohorts confirmed the prognostic value of ReCAL. In multivariable models, higher ReCAL expression was associated with poor OS (Changhai, HR, 3.391; 95%CI, 2.741-4.386; P=1.344E-14; Changzheng, HR, 2.473; 95%CI, 1.062-3.251; P=0.044; Nanjing, HR, 2.409; 95%CI, 1.097-3.210; P=0.037). ReCAL was particularly prognostic among patients with low-risk Mayo Clinic SSIGN score tumors. Patients with low ReCAL expression showed improved response after sunitinib (HR, 0.157; 95%CI, 0.033-0.744; P=0.020) or sorafenib (HR, 0.470; 95%CI, 0.229-0.646; P=0.031) treatment.ConclusionHigh ReCAL is an independent prognostic biomarker for poor outcome and a predictive biomarker for poor targeted therapy response in ccRCC patients.

参考文献/References:

[1]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin 2017,67(1):7-30.
[2]Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017,3:17009.doi: 10.1038/nrdp.2017.9.
[3]Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline[J]. J Urol, 2017,198(3):520-529.
[4]Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017,35(6):668-680.
[5]Zigeuner R, Hutterer G, Chromecki T,et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology[J]. Eur Urol, 2010,57(1):102-109.
[6]刘国安，赖江琼，梁礼平，等.彩色多普勒超声检查对肾癌诊断及分期的临床价值[J]. 东南国防医药,2015,17（6）:613-615.
[7]Ljungberg B, Bensalah K, Canfield S,et al. EAU guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol，2015,67(5):913-924.
[8]Brooks SA, Brannon AR, Parker JS,et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma[J]. Eur Urol，2014,66(1):77-84.
[9]Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies[J]. Lancet Oncol, 2015,16(6):676-685.
[10]Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer[J]. J Clin Invest, 2016, 126(8):2775-2282.
[11]张国华，徐颖，邹晨，等.长链非编码RNA DGCR5在胃癌中的表达及临床意义［J］．医学研究生学报，2018，31(1)：33-38.
[12]韩艳玲，周梦良，王汉东.长链非编码RNA MTHFD2基因在胶质母细胞瘤的表达及生物学功能［J］．医学研究生学报，2019，32(4)：369-373.
[13]Xu Z, Yang F, Wei D, et al. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma[J]. Oncogene，2017,36(14):1965-1977.
[14]Qu L, Wu Z, Li Y,et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells[J]. Nat Commun, 2016,7:12692.doi: 10.1038/ncomms12692.
[15]Qu L, Ding J, Chen C,et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J]. Cancer Cell, 2016,29(5):653-668.
[16]Yan X, Hu Z, Feng Y, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers[J]. Cancer Cell, 2015,28(4):529-540.
[17]Iyer MK, Niknafs YS, Malik R,et al. The landscape of long noncoding RNAs in the human transcriptome[J]. Nat Genet, 2015,47(3):199-208.
[18]Du Z, Fei T, Verhaak RG,et al. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer[J]. Nat Struct Mol Biol, 2013,20(7):908-913.
[19]McShane LM, Altman DG, Sauerbrei W,et al. Reporting recommendations for tumor marker prognostic studies (REMARK)[J]. J Natl CancerInst，2005,97(16):1180-1184.
[20]Scelo G, Riazalhosseini Y, Greger L,et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe[J]. Nat Commun, 2014,5:5135.
[21]Sato Y, Yoshizato T, Shiraishi Y,et al. Integrated molecular analysis of clear-cell renal cell carcinoma[J]. Nat Genet, 2013,45(8):860-867.
[22]Network CGAR. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature, 2013,499(7456):43-49.
[23]Copas JB. Using regression models for prediction: shrinkage and regression to the mean[J]. Stat Methods Med Res, 1997,6(2):167-183.
[24]Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression[J]. Stat Med, 1995,14(15):1707-1723.
[25]Peduzzi P, Concato J, Feinstein AR,et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates[J]. J Clin Epidemiol, 1995,48(12):1503-1510.
[26]陈贤明， 黄少华， 杨帆，等.影响鼻咽癌预后的相关因素分析[J]. 东南国防医药,2014,16（6）:584-586.
[27]Maroto P, Rini B. Molecular Biomarkers in Advanced Renal Cell Carcinoma[J]. Clin Cancer Res, 2014,20(8):2060-2071.
[28]Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2017,376(4):354-666.
[29]Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma[J]. Nat Rev Nephrol, 2017,13(8):496-511.
[30]Molina A, Lin X, Korytowsky B,et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials[J]. EurJ Cancer, 2014,50(2):351-358.
[31]Heng DY, Xie W, Regan MM,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study[J]. J Clin Oncol, 2009,27(34):5794-5799.
[32]Albiges L, Choueiri T, Escudier B,et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer[J]. Eur Urol，2015,67(1):100-110.

相似文献/References:

[1]刘国安,赖江琼,梁礼平,等.彩色多普勒超声检查对肾癌诊断及分期的临床价值[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):613.[doi:10.3969/j.issn.1672-271X.2015.06.016]
　LIU Guo-an,LAI Jiang-qiong,LIANG Li-ping,et al.The diagnostic value of color Doppler flow imaging in renal cell carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(04):613.[doi:10.3969/j.issn.1672-271X.2015.06.016]
[2]王微,王岩,王超君,等.长链非编码RNA HIF1α-AS1在血管内皮细胞缺氧损伤中的作用研究[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):1.
　WANG Wei,WANG Yan,WANG Chao-jun,et al.The study on long non-coding RNA hypoxia-inducible factor-1α-antisense RNA1 in hypoxic injury of vascular endothelial cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):1.
[3]祁娜,白田妹,徐天朝.外周血单个核细胞TMEVPG1、NRON的表达与精神分裂症患者症状和认知功能的关系[J].医学研究与战创伤救治(原医学研究生学报),2022,24(2):152.[doi:10.3969/j.issn.1672-271X.2022.02.009]
　QI Na,BAI Tian-mei,XU Tian-chao.The relationship between the expression of TMEVPG1 and NRON in peripheral blood mononuclear cells and the symptoms and cognitive function of schizophrenia[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):152.[doi:10.3969/j.issn.1672-271X.2022.02.009]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-08-10